Navigation Links
Dalton and AdeTherapeutics Enter Into a Manufacturing Services Agreement
Date:1/6/2011

TORONTO, Jan. 6, 2011 /PRNewswire/ -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Clinical Manufacturing Services Agreement with AdeTherapeutics (a day' therapeutics), Inc., a specialty pharma company based in Saskatoon, Saskatchewan, focused on providing quality therapeutic options in inflammation and acute care medicine. Dalton will provide aseptic fill/finish services under cGMP, for ADE's sterile anti-adhesion (scar tissue reduction) product.

"Our Establishment License from Health Canada, combined with our expert capabilities in analytical services and aseptic manufacturing, solidified the manufacturing agreement," said Peter Pekos, President and CEO. "Dalton is pleased to add this strategic relationship to our growing list of innovative pharmaceutical clients.  We are thrilled to be working with AdeTherapeutics and look forward to rapidly moving their product through their key milestones," continued Pekos.

Sanj Singh, President and Chief Executive Officer of AdeTherapeutics remarked, "The partnership with Dalton is a key part of AdeTherapeutics capital efficient virtual drug development model where we work with expert service providers from all over the globe to rapidly bring our novel therapeutics and diagnostics forward benefiting the healthcare community with safe, reliable and cost-effective treatment choices. We are excited about the opportunity to partner with a company whose client focus and commitment to quality match our own. Sharing these values with partners like Dalton is vital to our ability to provide products which fulfill the therapeutic needs of physicians and their patients. Surgeries are expected to double in the next five years and with no established standard of care, we are optimistic that our lead anti-adhesion candidate can solve this high unmet medical need."

About Dalton

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and aseptic filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients. Further information can be found at http://www.dalton.com.

About AdeTherapeutics, Inc.

AdeTherapeutics, Inc. is a privately-held clinical-stage drug development company headquartered in Saskatoon, SK.  Focused in the areas of inflammation and acute care medicine, AdeTherapeutics' business strategy is to build a robust portfolio of high value products by developing and/or in-licensing clinical-stage ready therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. The Company's most advanced therapeutic is a safe and effective anti-adhesion product that significantly reduces scar tissue adhesions caused by surgeries.


'/>"/>
SOURCE Dalton Pharma Services
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dalton Pharma Services Announces Successful Completion of Health Canada Inspection
2. Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services
3. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
4. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
5. UAS Laboratories Enters Into Agreement to Launch New Probiotic Product at Expo West
6. HRC Medical Center Offers Patients Relief with Innovative Bio-Identical Hormone Replacement Therapy
7. Zenobia Therapeutics, Inc. Enters Into a Research Collaboration With Lundbeck for the Parkinsons Disease Target LRRK2
8. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
9. Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share
10. Worlds smallest battery created at CINT nanotechnology center
11. Shrink Nanotechnologies Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
(Date:6/22/2016)... 2016   ViaCyte, Inc. , a privately-held regenerative ... replacement therapy for the treatment of diabetes in clinical-stage ... Meeting.  ISSCR 2016, the Global Stem Cell Event, is ... in San Francisco.    ... follows:Event: , Focus Session: Tools for Basic and Applied ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):